Human VEGFR3/Flt-4 Antibody

Catalog # Availability Size / Price Qty
VEGFR3/Flt‑4 in Human Cervical Squamous Metaplasia.
1 Image
Product Details
Citations (16)
Supplemental Products

Human VEGFR3/Flt-4 Antibody Summary

Species Reactivity
Detects human VEGFR3/Flt-4 in direct ELISAs and Western blots. In Western blots, approximately 15% cross-reactivity with recombinant mouse VEGFR3 is observed and less than 2% cross-reactivity with recombinant human VEGFR1 is observed.
Polyclonal Goat IgG
Antigen Affinity-purified
Mouse myeloma cell line NS0-derived recombinant human VEGFR3/Flt-4
Accession # P35916
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.


Recommended Concentration
Western Blot
0.1 µg/mL
Recombinant Human VEGFR3/Flt‑4 Fc Chimera (Catalog # 349-F4)
5-15 µg/mL
See below

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Immunohistochemistry VEGFR3/Flt-4 antibody in Human Cervical Squamous Metaplasia by Immunohistochemistry (IHC-P). View Larger

VEGFR3/Flt‑4 in Human Cervical Squamous Metaplasia. VEGFR3/Flt-4 was detected in immersion fixed paraffin-embedded sections of human cervical squamous metaplasia using Human VEGFR3/Flt-4 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF349) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Preparation and Storage

Reconstitute at 0.2 mg/mL in sterile PBS.
Reconstitution Buffer Available
Reconstitution Buffer 1 (PBS)
Catalog #
Size / Price
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGFR3/Flt-4

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1) and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis.

VEGFR3 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 24 aa residue signal peptide. Mature VEGFR3 is composed of a 751 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF-C and VEGF-D have been shown to bind and activate VEGFR3 (Flt-4). VEGFR3 is widely expressed in the early embryo but becomes restricted to lymphatic endothelia at later stages of development. It is likely that VEGFR3 may be important for lymph angiogenesis.

  1. Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.
Long Name
Vascular Endothelial Growth Factor Receptor 3
Entrez Gene IDs
2324 (Human); 14257 (Mouse)
Alternate Names
EC 2.7.10; EC; FLT4; Flt-4; fms-related tyrosine kinase 4; LMPH1A; PCLFLT41; soluble VEGFR3 variant 1; soluble VEGFR3 variant 2; soluble VEGFR3 variant 3; Tyrosine-protein kinase receptor FLT4; vascular endothelial growth factor receptor 3; VEGF R3; VEGFR3; VEGFR-3; VEGFR3Fms-like tyrosine kinase 4

Product Datasheets

You must select a language.


Citations for Human VEGFR3/Flt-4 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

16 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Cysteine oxidation of copper transporter CTR1 drives VEGFR2 signalling and angiogenesis
    Authors: A Das, D Ash, AY Fouda, V Sudhahar, YM Kim, Y Hou, FZ Hudson, BK Stansfield, RB Caldwell, M McMenamin, R Littlejohn, H Su, MR Regan, BJ Merrill, LB Poole, JH Kaplan, T Fukai, M Ushio-Fuka
    Nature Cell Biology, 2022;24(1):35-50.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Immunoprecipitation
  2. REDD1 is a determinant of low-dose metronomic doxorubicin-elicited endothelial cell dysfunction through downregulation of VEGFR-2/3 expression
    Authors: M Park, J Kim, T Kim, S Kim, W Park, KS Ha, SH Cho, MH Won, JH Lee, YG Kwon, YM Kim
    Experimental & Molecular Medicine, 2021;0(0):.
    Species: Human
    Sample Types: Cell Lysate
    Applications: Western Blot
  3. Cellular crosstalk regulates the aqueous humor outflow pathway and provides new targets for glaucoma therapies
    Authors: BR Thomson, P Liu, T Onay, J Du, SW Tompson, S Misener, RR Purohit, TL Young, J Jin, SE Quaggin
    Nature Communications, 2021;12(1):6072.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  4. The role of antibody expression and their association with bladder cancer recurrence: a single-centre prospective clinical-pilot study in 35 patients
    Authors: P Ella-Tongw, RM Lamb, A Makanga, I Shergill, SF Hughes
    BMC Urol, 2020;20(1):187.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  5. VEGFR3 Modulates Vascular Permeability by Controlling VEGF/VEGFR2 Signaling
    Authors: K Heinolaine, S Karaman, G D'Amico, T Tammela, R Sormunen, L Eklund, K Alitalo, G Zarkada
    Circ. Res, 2017;0(0):.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  6. Lymphatic endothelial progenitors originate from plastic myeloid cells activated by toll-like receptor-4
    Authors: LD Volk-Drape, KL Hall, AC Wilber, S Ran
    PLoS ONE, 2017;12(6):e0179257.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  7. TGF-?1 Is Present at High Levels in Wound Fluid from Breast Cancer Patients Immediately Post-Surgery, and Is Not Increased by Intraoperative Radiation Therapy (IORT)
    PLoS ONE, 2016;11(9):e0162221.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  8. Specific niches for lung-resident memory CD8+ T cells at the site of tissue regeneration enable CD69-independent maintenance
    Authors: Masaaki Miyazawa
    J. Exp. Med., 2016;0(0):.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC-Fr
  9. Effects of neuregulin GGF2 (cimaglermin alfa) dose and treatment frequency on left ventricular function in rats following myocardial infarction
    Authors: Tom J Parry
    Eur. J. Pharmacol, 2016;796(0):76-89.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Western Blot
  10. Primary Tumor-Secreted Lymphangiogenic Factors Induce Pre-Metastatic Lymphvascular Niche Formation at Sentinel Lymph Nodes in Oral Squamous Cell Carcinoma.
    Authors: Wakisaka N, Hasegawa Y, Yoshimoto S, Miura K, Shiotani A, Yokoyama J, Sugasawa M, Moriyama-Kita M, Endo K, Yoshizaki T
    PLoS ONE, 2015;10(12):e0144056.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  11. Expression of vascular endothelial growth factor-C and vascular endothelial growth factor receptor-3 in esophageal squamous cell carcinoma.
    Authors: Omoto, Itaru, Matsumoto, Masataka, Okumura, Hiroshi, Uchikado, Yasuto, Setoyama, Tetsuro, Kita, Yoshiaki, Owaki, Tetsuhir, Kijima, Yuko, Shinchi, Hiroyuki, Ishigami, Sumiya, Ueno, Shinichi, Natsugoe, Shoji
    Oncol Lett, 2014;7(4):1027-1032.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  12. VEGF-D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma.
    Authors: Thelen A, Scholz A, Benckert C, Von Marschall Z, Schroder M, Wiedenmann B, Neuhaus P, Rosewicz S, Jonas S
    Int. J. Cancer, 2008;122(11):2471-81.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  13. All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells.
    Authors: Bairey O, Boycov O, Kaganovsky E, Zimra Y, Shaklai M, Rabizadeh E
    Leuk. Res., 2004;28(3):243-8.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  14. Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma.
    Authors: Su JL, Shih JY, Yen ML, Jeng YM, Chang CC, Hsieh CY, Wei LH, Yang PC, Kuo ML
    Cancer Res., 2004;64(2):554-64.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  15. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops.
    Authors: Masood R, Kundra A, Zhu S, Xia G, Scalia P, Smith DL, Gill PS
    Int. J. Cancer, 2003;104(5):603-10.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Immunoprecipitation
  16. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma.
    Authors: Yokoyama Y, Charnock-Jones DS, Licence D, Yanaihara A, Hastings JM, Holland CM, Emoto M, Sakamoto A, Sakamoto T, Maruyama H, Sato S, Mizunuma H, Smith SK
    Clin. Cancer Res., 2003;9(4):1361-9.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P


No product specific FAQs exist for this product, however you may

View all Antibody FAQs

Isotype Controls

Reconstitution Buffers

Secondary Antibodies

Reviews for Human VEGFR3/Flt-4 Antibody

There are currently no reviews for this product. Be the first to review Human VEGFR3/Flt-4 Antibody and earn rewards!

Have you used Human VEGFR3/Flt-4 Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review